AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
AMCP Publishes New Pay-for-Performance Principles; AMCP Joins Public Health Leaders in Defense of OSHA’s COVID-19 Vaccine Rule; AMCP Supports Dr. Robert Califf’s Nomination for FDA Commissioner; ICYMI: AMCP Quarterly Legislative and Regulatory Briefing Now Available; Reps. DeGette and Upton Release the Cures 2.0 Act; AMCP Seeking New Regulatory Affairs Director.
AMCP Submits Comments on PDUFA; AMCP Joins Influenza Antiviral Sign-on Letter; AMCP Joins COVID-19 Antiviral Recommendations Sign-on Letter; President Biden Signs Infrastructure Investment and Jobs Act; President Biden To Nominate Dr. Robert Califf for FDA Commissioner.
AMCP Celebrates Grassroots Advocates at Nexus 2021; Congress Passes Continuing Resolution to Avoid Government Shutdown; Raises Debt Ceiling to Avert Default; FDA and CDC Approve Pfizer Booster; CMS Releases 2022 Premiums and Cost-Sharing Information for Medicare Advantage & Part D Plans; CMS Releases MA, Part D Star Ratings for 2022; MACPAC Report on Medicaid Churn.
Join us for a Grassroots Reception at Nexus 2021; Expanding Access to COVID-19 Therapeutics –HHS PREP Act Declaration: Ninth Amendment; HHS Comprehensive Plan for Addressing High Drug Prices; AMCP Virtual Legislative Days 2021; ICYMI: Respond to AMCP Policy Action Items Survey; AMCP Urges Congress to Implement Continuous Eligibility for Children in Medicaid and CHIP.
AMCP Urges HHS to Extend Medicare Part D Enhanced MTM Mode; Biden Administration Withdraws the Most Favored Nations Model; AMCP Supports FDA Approval of Biosimilar Insulin; President Biden Calls on Congress to Reduce Drug Prices.
AMCP Submits Comments on OMB Equity RFI; President Biden Signs Executive Order on Increasing Competition; CMS Opens National Coverage Determination Process for Aduhelm; Congress Releases 21st Century Cures 2.0 Discussion Draft.
